tirzepatide fda approval date for Zepbound: FSU researcher available for context on newly approved weight loss treatment FDA approves tirzepatide (Zepbound) injection

Wegovy, containing semaglutide , is approved for weight management in adults and children over 12 with obesity

Individuals should ensure that they take adequate vitamin D (Sunlight/Supplements if required)

Novo is testing a combination of cagrilintide and semaglutide -- the latter of which is known under the brand name Wegovy -- that produced about a 22% weight loss in people with obesity but not diabetesin a previously published, late-stage clinical trial.

What your provider will discuss with you Current BMI, weight history, prior weight-management approaches Personal or family history of medullary thyroid carcinoma or MEN2 History of pancreatitis, gallbladder disease, or diabetic retinopathy Pregnancy, pregnancy plans, or breastfeeding Current medications, especially other diabetes medications or insulin Realistic expectations, lifestyle context, and follow-up cadence Considerations Published literature on incretin-class therapy commonly notes gastrointestinal effects (nausea, decreased appetite, constipation), particularly during dose escalation

Without insurance coverage, the cost of Wegovy is more likely to be expensive

There is, however, a potential hazard to be aware of